IMV Inc.

OTCPK:IMVI.F Stock Report

Market Cap: US$14.0

IMV Past Earnings Performance

Past criteria checks 0/6

There is insufficient data on IMV's performance over the last few years.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Biotechs Industry Growth17.04%
Revenue growth raten/a
Return on equityn/a
Net Marginn/a
Last Earnings Update31 Dec 2022

Recent past performance updates

Recent updates

Seeking Alpha Sep 15

IMV to cut ~33% workforce amid reorganization

IMV (NASDAQ:IMV) said it was undertaking a reorganization and reducing its workforce by nearly one third. The company will focus on its DPX platform and advance its lead DPX asset Maveropepimut-S (MVP-S), IMV said in a Sept. 15 press release. IMV intends to focus its resources on ongoing MVP-S clinical programs in immuno-oncology (IO), notably phase 2b trials VITALIZE in relapsed/ refractory Diffuse Large B Cell Lymphoma (DLBCL) and AVALON for advanced metastatic ovarian cancer. In addition, the Canadian company said that Saman Maleki was appointed to the board replacing Brittany Davison who will be promoted to chief accounting officer from her current role as senior vice president, Finance. Maleki is an Assistant Professor of Oncology, Pathology & Laboratory Medicine, and Medical Biophysics at Western University and is an expert in the field of immuno-oncology, according to IMV. IMV +4.05% to $0.77 premarket Sept. 15
Seeking Alpha Jul 08

IMV receives Nasdaq non-compliance letter

IMV (NASDAQ:IMV) received a letter from Nasdaq for not meeting the minimum bid price of $1.00 per share required for continued listing. Company may be eligible for an additional 180 calendar days to regain compliance.

Revenue & Expenses Breakdown

How IMV makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

OTCPK:IMVI.F Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 220-38170
30 Sep 220-41170
30 Jun 220-43180
31 Mar 220-40170
31 Dec 210-37160
30 Sep 210-32150
30 Jun 210-28130
31 Mar 210-26120
31 Dec 200-26110
30 Sep 200-25100
30 Jun 200-2490
31 Mar 200-2280
31 Dec 190-2180
30 Sep 190-2070
30 Jun 190-1970
31 Mar 190-1970
31 Dec 180-1670
30 Sep 180-1570
30 Jun 180-1260
31 Mar 180-1050
31 Dec 170-1050
30 Sep 170-940
30 Jun 170-84-1
31 Mar 170-73-1
31 Dec 160-730
30 Sep 160-631
30 Jun 160-633
31 Mar 160-734
31 Dec 150-633
30 Sep 150-633

Quality Earnings: Insufficient data to determine if IMVI.F has high quality earnings.

Growing Profit Margin: Insufficient data to determine if IMVI.F's profit margins have improved over the past year.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if IMVI.F's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Insufficient data to compare IMVI.F's past year earnings growth to its 5-year average.

Earnings vs Industry: Insufficient data to determine if IMVI.F's earnings growth over the past year exceeded the Biotechs industry average.


Return on Equity

High ROE: IMVI.F has a negative Return on Equity (0%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/09 04:44
End of Day Share Price 2026/06/02 00:00
Earnings2022/12/31
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

IMV Inc. is covered by 8 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Sarah ChiassonBeacon Securities Limited
Mayank MamtaniB. Riley Securities, Inc.
Thomas ShraderBTIG